Monthly Archives: May 2019

Dapagliflozin–saxagliptin ‘attractive’ options for patients with type 2 diabetes with chronic kidney disease

MedwireNews (April 16, 2019): Dapagliflozin, with or without saxagliptin, reduces albuminuria in people with type 2 diabetes and moderate-to-severe chronic kidney disease when used in combination with antihypertensive treatments, DELIGHT study data show. Furthermore, using the sodium-glucose co-transporter (SGLT)2 inhibitor … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment